Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 2:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 14,965 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Digestive System Clear all
Terminated Phase 2 Interventional

A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer

NCT00516841
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Neoplasms
Interventions
Volociximab
Drug
Lead sponsor
Facet Biotech
Industry
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
19
States / cities
Los Angeles, California • Orange, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2012 · Synced Oct 30, 2026, 2:57 PM EDT
Terminated No phase listed Observational

YASU Research Registry: For Young Adults With Cancer

NCT06275854
View directory record Official record
Conditions
Cancer, Leukemia, Sarcoma, Germ Cell Cancer, Lymphoma, Colorectal Cancer, Melanoma, Breast Cancer
Interventions
Not listed
Lead sponsor
Young Adult Survivors United
Other
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Wexford, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 30, 2026, 2:57 PM EDT
Active, not recruiting Not applicable Interventional

TACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients

NCT01918683
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
TACE transarterial chemoembolization, stereotatic body radiotherapy (SBRT)
Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
3
States / cities
Maywood, Illinois • Portland, Oregon • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 30, 2026, 2:57 PM EDT
Completed Phase 2 Interventional Results available

Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer

NCT03800602
View directory record Official record
Conditions
Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Refractory Colorectal Carcinoma, Stage IV Colorectal Cancer, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer, Stage IVC Colorectal Cancer, Colorectal Cancer Metastatic
Interventions
Metformin, Nivolumab
Drug · Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 5, 2024 · Synced Oct 30, 2026, 2:57 PM EDT
Completed Not applicable Interventional Results available

CPAP to Improve Swallow Function Post Total Laryngectomy

NCT03328702
View directory record Official record
Conditions
Oropharyngeal Dysphagia, Laryngectomy; Status
Interventions
Continuous Positive Airway Pressure
Device
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 24, 2024 · Synced Oct 30, 2026, 2:57 PM EDT
Terminated Phase 1 Interventional

A Study of SGN-CD228A in Advanced Solid Tumors

NCT04042480
View directory record Official record
Conditions
Cutaneous Melanoma, Pleural Mesothelioma, HER2 Negative Breast Neoplasms, Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
Interventions
SGN-CD228A
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Oct 30, 2026, 2:57 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Investigate The Effect Of Solabegron (GW427353) On Gastrointestinal Transit In Healthy Volunteers

NCT00401479
View directory record Official record
Conditions
Irritable Bowel Syndrome (IBS)
Interventions
Placebo, Solabegron (GW427353)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 16, 2008 · Synced Oct 30, 2026, 2:57 PM EDT
Not listed Phase 2 Interventional

Effect of Hemp-CBD on Patients With CIPN

NCT04398446
View directory record Official record
Conditions
Chemotherapy-induced Peripheral Neuropathy, Colorectal Cancer Stage II, Colorectal Cancer Stage III, Breast Cancer, Ovarian Cancer, Uterine Cancer, Pancreatic Cancer
Interventions
Hemp-based CBD, Placebo oral tablet
Drug · Other
Lead sponsor
Main Line Health
Other
Eligibility
21 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Wynnewood, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Oct 30, 2026, 2:57 PM EDT
Withdrawn Phase 2 Interventional

Evaluation of the Safety and Efficacy of TXA127 (Angiotensin 1-7) to Enhance Engraftment in Pediatric Patients Undergoing Single or Double Umbilical Cord Blood Transplantation

NCT01554254
View directory record Official record
Conditions
Cord Blood Transplant, Hematologic Malignancy, Inherited Metabolic Disease
Interventions
TXA127
Drug
Lead sponsor
Tarix Pharmaceuticals
Industry
Eligibility
6 Months to 20 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 31, 2016 · Synced Oct 30, 2026, 2:57 PM EDT
Recruiting Not applicable Interventional

Developing a Self-Management Intervention to Improve Health Outcomes for Patients With Inflammatory Bowel Disease

NCT07456566
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease
Interventions
Digital self-management program, Standard Care
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 30, 2026, 2:57 PM EDT
Recruiting No phase listed Observational

Sample Collection for Ongoing Research and Product Evaluation Study

NCT07318051
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Muscle Invasive Bladder Cancer, Rectal Cancer, Pancreatic Cancer, Ovarian Cancer, Gastroesophageal Cancer, Prostate Cancer, Melanoma, Head and Neck Cancer, Uterine Cancer, Liver Cancer
Interventions
Not listed
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years and older
Enrollment
9,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 30, 2026, 2:57 PM EDT
Completed Phase 1 Interventional

A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer

NCT02860780
View directory record Official record
Conditions
Advanced Cancer, Metastatic Cancer, Colorectal Cancer, Non-small Cell Lung Cancer
Interventions
prexasertib, ralimetinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Charlotte, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 14, 2018 · Synced Oct 30, 2026, 2:57 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Diabetes/ Endocrine Surveillance in SDS

NCT04275479
View directory record Official record
Conditions
Shwachman-Diamond Syndrome
Interventions
Oral Glucose Tolerance Test, Modified Oral Glucose Tolerance Test, Modified Mixed Meal Tolerance Test, Continuous Glucose Monitor, Food Diary, Medical History Questionnaires
Diagnostic Test · Other · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
3 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 30, 2026, 2:57 PM EDT
Completed Phase 1 Interventional

Study To Determine The Maximum Range of Light Doses At Two HPPH Doses With Acceptable Normal Tissue Toxicity For PDT Treatment Of High Grade Dysplasia,CIS or Early Adenocarcinoma In Barrett's Esophagus

NCT01238042
View directory record Official record
Conditions
Barrett's Esophagus, CIS, HGD
Interventions
HPPH
Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Oct 30, 2026, 2:57 PM EDT
Completed Phase 1Phase 2 Interventional

A Study Evaluating IPI-926 in Combination With Gemcitabine in Patients With Metastatic Pancreatic Cancer

NCT01130142
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
IPI-926 plus gemcitabine, Placebo plus gemcitabine
Drug
Lead sponsor
Infinity Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
25
States / cities
Tucson, Arizona • San Diego, California • San Francisco, California + 21 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 30, 2026, 2:57 PM EDT
Terminated Phase 1Phase 2 Interventional

A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

NCT05363605
View directory record Official record
Conditions
Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma, Bladder Carcinoma, Susceptible FGFR3 Genetic Alterations, FGFR3, FGFR3 Overexpression, FGFR3 Receptor, FGFR3 Protein Overexpression, Ovarian Cancer, Colorectal Cancer, Breast Cancer, Liver Cancer, Lung Cancer, Gastric Cancer
Interventions
[225Ac]-FPI-1966, [111In]-FPI-1967, vofatamab
Drug · Biological
Lead sponsor
Fusion Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Duarte, California • San Francisco, California • Iowa City, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Oct 30, 2026, 2:57 PM EDT
Terminated Phase 2 Interventional Results available

Clinical And Translational Study Of MK-2206 In Patients With Metastatic KRAS-Wild-Type, PIK3CA-Mutated, Colorectal Cancer

NCT01186705
View directory record Official record
Conditions
Colon Cancer, Rectal Cancer
Interventions
MK-2206
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2015 · Synced Oct 30, 2026, 2:57 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Digital Mind Body Intervention Among Black and Hispanic Patients Living With Inflammatory Bowel Disease

NCT06510296
View directory record Official record
Conditions
Crohn's Disease, Ulcerative Colitis, Inflammatory Bowel Diseases
Interventions
Digital Mind Body Intervention mobile application
Behavioral
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2028
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 30, 2026, 2:57 PM EDT
Completed Not applicable Interventional

Continuous Cardiorespiratory Monitoring in Cystic Fibrosis

NCT04489186
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Wearable device
Device
Lead sponsor
Byteflies
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Oct 30, 2026, 2:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Geriatric Communication Skills Training Program for Oncology Clinicians

NCT03530969
View directory record Official record
Conditions
GI Cancer, Lymphoma, GU Cancer, Bone Marrow Transplant
Interventions
Self-Efficacy Assessment, UCLA Geriatrics Attitudes Scale, Course Evaluations, The Consultation and Relational Empathy (CARE) questionnaire, Consumer Assessment of Health Care Providers and Systems Program (CAHPS), Patient activation measure (PAM) scale
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 30, 2026, 2:57 PM EDT
Completed Phase 2 Interventional Results available

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

NCT02091141
View directory record Official record
Conditions
Neoplasms, Solid Tumors, Biliary Cancer, Salivary Cancer, Bladder Cancer
Interventions
Trastuzumab, Pertuzumab, Erlotinib, Vemurafenib, Cobimetinib, Vismodegib, Alectinib, Atezolizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
673 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
60
States / cities
Goodyear, Arizona • Phoenix, Arizona • Springdale, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Oct 30, 2026, 2:57 PM EDT
Enrolling by invitation No phase listed Observational

Improving the Quality of Care for Adults With Inflammatory Bowel Disease

NCT02791854
View directory record Official record
Conditions
Crohn's Disease, Ulcerative Colitis, Inflammatory Bowel Diseases
Interventions
Not listed
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2030
U.S. locations
29
States / cities
Los Angeles, California • Newport Beach, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Oct 30, 2026, 2:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Broccoli Extract Supplementation in Older Adults With Alcohol Use Disorder

NCT05902754
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Generally Recognized as Safe - Sulforaphane, Placebo
Dietary Supplement
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
50 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 30, 2026, 2:57 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy Followed by Surgery in Treating Patients With Stomach Cancer

NCT00004103
View directory record Official record
Conditions
Gastric Cancer
Interventions
cisplatin, floxuridine, irinotecan hydrochloride, adjuvant therapy, conventional surgery, neoadjuvant therapy
Drug · Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2011 · Synced Oct 30, 2026, 2:57 PM EDT